IL6R and coronary artery disorder: A previous MR analysis suggested that reduced IL-6 signalling (modelled using rs2228145 alone) could reduce inflammation and risk of coronary heart disease [16], leading to clinical trials of monoclonal antibodies targeting either IL6R or IL-6 for coronary disease prevention [12].